Search

Search Results

• 

  Incidence of influenza-like illness into a cohort of patients affected by chronic inflammatory rheumatism and treated with biological agents

  S.L. Bello, L. Serafino, C. Bonali, N. Terlizzi, C. Fanizza, C. Anecchino, G. Lapaldula

  299-306

  11-12-2012

  https://doi.org/10.4081/reumatismo.2012.299

  2259

  PDF: 1206
• 

  Drug survival and reasons for discontinuation of the first course of biological therapy in 301 juvenile idiopathic arthritis patients

  M. Romano, I. Pontikaki, M. Gattinara, I. Ardoino, C. Donati, P. Boracchi, P.L. Meroni, V. Gerloni

  278-285

  17-03-2014

  https://doi.org/10.4081/reumatismo.2013.682

  2630

  PDF: 1359
• 

  Association between the response to B cell depletion therapy and the allele*2 of the HS1,2A enhancer in seropositive rheumatoid arthritis patients

  S. Canestri, M.C. Totaro, E. Serone, B. Tolusso, D. Frezza, E. Gremese, G. Ferraccioli

  368-373

  20-12-2012

  https://doi.org/10.4081/reumatismo.2012.368

  2143

  PDF: 781
• 

  Psoriatic arthritis: treatment strategies using anti-inflammatory drugs and classical DMARDs

  E. Lubrano, R. Scarpa

  107-112

  05-06-2012

  https://doi.org/10.4081/reumatismo.2012.107

  1362

  PDF: 1197
• 

  The impact on disability of initial treatment with methotrexate in patients with rheumatoid arthritis: results from the MARI study

  M. Manara, L. Arcarese, G. Bianchi, V. Corbelli, O. Epis, R. Laurenti, A. Migliore, M. Muratore, A. Roncaglione, M. Rossini, M. Savo, L. Sinigaglia

  188-194

  31-12-2016

  https://doi.org/10.4081/reumatismo.2016.903

  1742

  PDF: 917
• 

  Psoriatic arthritis: treatment strategies using biologic agents

  S. D'Angelo, C. Palazzi, I. Olivieri

  113-121

  05-06-2012

  https://doi.org/10.4081/reumatismo.2012.113

  1253

  PDF: 1156
• 

  A short history of anti-rheumatic therapy - VI. Rheumatoid arthritis drugs

  G. Pasero, P. Marson

  111-123

  https://doi.org/10.4081/reumatismo.2011.111

  2203

  PDF: 1766
• 

  Psoriatic arthritis. When the heterogeneity requires normality

  L. Punzi, R. Ramonda

  59-65

  05-06-2012

  https://doi.org/10.4081/reumatismo.2012.59

  845

  PDF: 680

• Correlation between radiographic, echographic and MRI changes and rheumatoid arthritis progression

  M.A. Cimmino, M. Parodi, E. Silvestri, G. Garlaschi

  28-40

  https://doi.org/10.4081/reumatismo.2004.1s.28

  960

  PDF: 2929

• Safety of methotrexate in rheumatoid arthritis: a retrospective cohort study in clinical practice

  G. La Montagna, R. Tirri, R. Vitiello, D. Malesci, R. Buono, G. Mennillo, G. Valentini

  261-267

  https://doi.org/10.4081/reumatismo.2006.261

  1176

  PDF: 692

• Early rheumatoid arthritis: a prospective study on how to induce the remission

  T. Ziglioli, C. Bazzani, M. Filippini, S. Zingarelli, A. Giugno, R. Gorla

  131-135

  https://doi.org/10.4081/reumatismo.2008.131

  1004

  PDF: 676

• Treatment of spondyloarthritis with disease-modifying anti-rheumatic drugs during pregnancy and breastfeeding: comparing the recommendations and guidelines of the principal societies of rheumatology

  M. Manara, D. Bruno, M. Ferrito, S. Perniola, R.F. Caporali, E. Gremese

  11-09-2024

  https://doi.org/10.4081/reumatismo.2024.1781

  1588

  PDF: 827
• 

  Neutrophil-lymphocyte ratio, pain perception, and disease activity score may serve as important predictive markers for sustained remission in rheumatoid arthritis

  S. Chandrashekara, A. Rajendran, A. Bai Jaganath, R. Krishnamurthy

  109-115

  09-02-2016

  https://doi.org/10.4081/reumatismo.2015.838

  2942

  PDF: 1428
• 

  Three-dimensional morphological condylar and mandibular changes in a patient with juvenile idiopathic arthritis: interdisciplinary treatment

  G. Farronato, C. Bellintani, U. Garagiola, P. Cressoni, P. Sarzi Puttini, F. Atzeni, M. Cazzola

  254-257

  06-11-2014

  https://doi.org/10.4081/reumatismo.2014.725

  2492

  PDF: 1287
• 

  COVID-19 pandemic and biological therapy in rheumatologic disorders: how to deal with?

  Z. Ahmadinejad, R. Assari, N. Ayoobi Yazdi, S.-H. Mazloomi, P. Javanshayani, H. Khalili Afousi, V. Ziaee

  173-177

  19-11-2020

  https://doi.org/10.4081/reumatismo.2020.1289

  1604

  PDF: 993

• TNF-α gene polymorphisms in rheumatoid arthritis patients treated with anti-TNF-α agents: preliminary results

  M. Fabris, E. Di Poi, S. Sacco, G. Damante, L. Sinigaglia, G. Ferraccioli

  19-26

  https://doi.org/10.4081/reumatismo.2002.19

  1266

  PDF: 739

• Biological therapy with TNF-inhibitors in pediatric rheumatology. Review of the litterature and personal experience

  V. Gerloni, I. Pontikaki, M Gattinara, F. Fantini

  244-261

  https://doi.org/10.4081/reumatismo.2007.244

  1286

  PDF: 1104
• 

  Remission, low disease activity and improvement of pain and function in psoriatic arthritis patients treated with IL-12/23 and IL-17 inhibitors. A multicenter prospective study

  F.M. Perrotta, A. Delle Sedie, S. Scriffignano, P. Volpe, E. Cordisco, N. Milano, M. Gabini, E. Lubrano

  52-59

  10-04-2020

  https://doi.org/10.4081/reumatismo.2020.1266

  1920

  PDF: 1078

• Rheumatoid factor positivity rather than anti-CCP positivity, a lower disability and a lower number of anti-TNFα agents failed are associated with response to rituximab in rheumatoid arthritis

  L. Quartuccio, S. Salvin, M. Saracco, S. Lombardi, M. Fabris, E. Mansutti, M. Maset, S. Pellerito, S. De Vita

  182-186

  https://doi.org/10.4081/reumatismo.2009.182

  996

  PDF: 694

• IL-1Ra: its role in rheumatoid arthritis

  M. Cutolo

  41-45

  https://doi.org/10.4081/reumatismo.2004.1s.41

  1456

  PDF: 2286

• Early rheumatoid arthritis

  F. Atzeni, P. Sarzi-Puttini

  100-117

  https://doi.org/10.4081/reumatismo.2007.100

  1474

  PDF: 2087

• TNFα blockers and infectious risk in rheumatoid arthritis

  B. Raffeiner, C. Botsios, F. Ometto, L. Bernardi, A. Montante, P. Sfriso, S. Todesco, L. Punzi

  165-173

  https://doi.org/10.4081/reumatismo.2009.165

  1624

  PDF: 2106

• Long-term evaluation of infliximab in the treatment of persistently active juvenile idiopathic arthritis refractory to conventional therapy

  G. De Marco, V. Gerloni, I. Pontikaki, A. Lurati, B. Teruzzi, A. Salmaso, E. Valcamonica, M. Gattinara, F. Fantini

  50-56

  https://doi.org/10.4081/reumatismo.2007.50

  1125

  PDF: 756

• MonitorNet: studio italiano osservazionale multicentrico per la valutazione del profilo rischio-beneficio dei farmaci biologici nella pratica clinica reumatologica

  P. Sfriso, F. Salaffi, C.M. Montecucco, S. Bombardieri, S. Todesco

  132-139

  https://doi.org/10.4081/reumatismo.2009.132

  1900

  PDF: 1127

• The treatment of recurrent uveitis with TNFα inhibitors

  P.C.F. Falappone, F. Iannone, C. Scioscia, V. Grattagliano, M. Covelli, G. Lapadula

  185-189

  https://doi.org/10.4081/reumatismo.2004.185

  1726

  PDF: 2353

• Intra-articular etanercept treatment for severe diffuse pigmented villonodular knee synovitis

  U. Fiocco, P. Sfriso, F. Oliviero, F. Sovran, E. Scagliori, E. Pagnin, M. Vezzù, L. Cozzi, C. Botsios, R. Nardacchione, A. Di Maggio, L. Rubaltelli, C. Giacometti, F. Calabrese, S. Todesco

  268-274

  https://doi.org/10.4081/reumatismo.2006.268

  1529

  PDF: 2661

• Efficacy and safety of anti-TNF agents in the Lombardy rheumatoid arthritis network (LORHEN)

  P. Sarzi- Puttini, M. Antivalle, A. Marchesoni, E.G. Favalli, R. Gorla, M. Filippini, R. Caporali, F. Bobbio-Pallavicini, C. Montecucco, F. Atzeni

  290-295

  https://doi.org/10.4081/reumatismo.2008.290

  2051

  PDF: 1057

• Analysis of the kinetic of expression of tristetraprolin and HuR by rheumatoid arthritis patients pheripheral blood mononuclear cells stimulated with lipopolysaccharide

  M. Fabris, B. Tolusso, E. Gremese, P. Tomietto, G. Ferraccioli

  94-103

  https://doi.org/10.4081/reumatismo.2004.94

  1327

  PDF: 918

• Kidney involvement in rheumatoid arthritis

  A. Icardi, P. Araghi, M. Ciabattoni, U. Romano, P. Lazzarini, G. Bianchi

  76-85

  https://doi.org/10.4081/reumatismo.2003.76

  5500

  PDF: 7583

• New classification criteria for rheumatoid arthritis

  C.A. Scirè, R. Caproali

  159-162

  https://doi.org/10.4081/reumatismo.2010.159

  2069

  PDF: 8952

• Ultrasonographic assessment of the response to Etanercept treatment in patients with rheumatoid arthritis

  A. Iagnocco, C. Perella, F. Ceccarelli, E. Tripodo, C. Alessandri, L. Magrini, G. Valesini

  233-238

  https://doi.org/10.4081/reumatismo.2006.233

  1014

  PDF: 981

• The risk/benefit profile of biologic drugs in real-world rheumatology practice. From ANTARES to MonitorNet

  P. Sfriso, F. Salaffi, S. Bombardieri, B. Canesi, C.M. Montecucco, S. Todesco

  77-84

  https://doi.org/10.4081/reumatismo.2008.77

  1773

  PDF: 822

• Socio-demographic aspects and therapeutic pathways in patients with rheumatoid arthritis in Italy

  F. Salaffi, C.M. Vaccaro, T. Manacorda, L. Pardini, C.M. Montecucco

  197-211

  https://doi.org/10.4081/reumatismo.2009.197

  1169

  PDF: 895

• IL-1Ra (recombinant human IL-1 receptor antagonist) in the treatment of rheumatoid arthritis: the efficacy

  U. Fiocco, M. Vezzù, L. Cozzi, S. Todesco

  62-73

  https://doi.org/10.4081/reumatismo.2004.1s.62

  1264

  PDF: 1907